Drug Profile


Alternative Names: Acetylcysteine/oxpentifylline; Oxpentifylline/acetylcysteine; Pentoxifylline/acetylcysteine; PTL-202

Latest Information Update: 27 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pacific Therapeutics
  • Class Antifibrotics; Reducing agents; Small molecules; Sulfur amino acids; Xanthines
  • Mechanism of Action Antioxidants; Cytokine inhibitors; Free radical scavengers; Phosphoric diester hydrolase inhibitors; Platelet aggregation inhibitors; Transforming growth factor beta inhibitors; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Idiopathic pulmonary fibrosis

Most Recent Events

  • 08 May 2014 Acetylcysteine/pentoxifylline is still in phase I trials for Pulmonary fibrosis
  • 04 Feb 2014 Pacific Therapeutics terminates its technology licence with Dalhousie University in Canada
  • 22 Aug 2012 Phase-I clinical trials in volunteers in India (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top